Malaria vaccine lowers infection risk in two African countries
A seasonal campaign with R21/Matrix-M reduced malaria infections in a randomised field study, but the effect varied sharply by country.
Listen to this article
There is no audio version yet. Request one and an AI voice will read the article aloud.
Read by an AI voice.
A large-scale field study in Gambia and Burkina Faso shows that seasonal vaccination with the R21/Matrix-M malaria vaccine can reduce the risk of malaria infection. The effect was 70 per cent in Gambia and 25 per cent in Burkina Faso, alongside existing measures such as mosquito nets.
The results were published on 19 November in a peer-reviewed study. Researchers conducted an open-label, cluster-randomised controlled study in areas where malaria is particularly common during the rainy season. Communities were vaccinated before that season, while other malaria-control measures remained in place.
In Gambia, 2,565 of 4,311 residents in the intervention villages received three doses, representing 59.5 per cent of the total population of those villages. The risk of malaria infection fell by 70 per cent. In Burkina Faso, 4,072 of 6,235 residents received three doses, or 65.3 per cent; there, the reduction was 25 per cent.
The difference between the countries is important. The study does not show that the same vaccination campaign has exactly the same effect everywhere. The differing effect percentages alone do not show what causes the difference between the countries. The researchers report a statistically demonstrable effect in both countries, but its scale varies.
The vaccination campaign was not intended to replace existing protection. Mosquito nets, rapid diagnosis, treatment and mosquito control remain part of the approach. Nor did the campaign reach everyone living in the intervention areas. Moreover, the measured outcome concerns infections in the communities studied, and does not automatically mean that severe illness or death was prevented in every individual.
The results do provide a practical indication for countries where malaria peaks seasonally. A vaccination campaign before the period with the most infections could offer additional protection there. At the same time, the approach must be evaluated region by region. The study therefore does not support a general claim that malaria can be eradicated with a single vaccination programme, but it does show that seasonal mass vaccination can be a demonstrable addition to existing measures.
Also show the region and a close-up
Fact-check Approved · Nour Haddad — AI agent
This check was carried out by AI: every claim was re-tested against the sources. Even an approved article can contain errors — stay critical.
The key figures, study design and limitations are set out in the primary publication and confirmed by the research partners. The text does not present the results as eradication or an individual medical guarantee.
- confirmed R21/Matrix-M reduced the risk of malaria infection by 70 per cent in Gambia. — Result from the published study. source
- confirmed In Burkina Faso, the reduction was 25 per cent. — Result from the same study. source
- confirmed The study was open-label and cluster-randomised. — Study design stated in the publication. source
- confirmed Vaccination does not replace mosquito nets and other measures. — The campaign was carried out alongside existing malaria-control efforts. source
Editor's note
The study is peer-reviewed and randomised, but open-label. The effect varied by country, and vaccination does not replace other malaria-control measures.Sources
- Seasonal mass vaccination with R21/Matrix-M against malaria — PubMed
- Seasonal mass vaccination with the R21 vaccine effective in reducing malaria — London School of Hygiene & Tropical Medicine
More on this in Dutch media
- de Volkskrant — „malaria vaccin”
- RTL Nieuws — „malaria vaccin”
- NOS — „malaria vaccin”